Deferoxamine: A reversible S-phase inhibitor of human lymphocyte proliferation

H. M. Lederman, A. Cohen, J. W.W. Lee

Research output: Contribution to journalArticlepeer-review

258 Scopus citations


Deferoxamine is widely used therapeutically as a chelator of ferric ion in disorders of iron overload. This study demonstrates that this drug is a potent inhibitor of DNA synthesis by human B and T lymphocytes in vitro, but has relatively little effect on the synthesis of RNA and protein. The inhibitory effects of deferoxamine are completely reversible by washing or by adding stoichiometric amounts of Fe3+. Micromolar concentrations of deferoxamine decrease intracellular levels of deoxyribonucleoside triphosphates, which is similar to the effects of hydroxyurea. The binding of iron by deferoxamine likely causes an inhibition of ribonucleotide reductase activity, thereby preventing cells from completing the S phase of the cell proliferation cycle. As a reversible and nontoxic S-phase inhibitor, it may have important experimental and therapeutic applications.

Original languageEnglish (US)
Pages (from-to)748-753
Number of pages6
Issue number3
StatePublished - 1984
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Deferoxamine: A reversible S-phase inhibitor of human lymphocyte proliferation'. Together they form a unique fingerprint.

Cite this